Portal Vein Thrombosis in Cirrhosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2013-10-31

Study Completion Date

2014-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the supervivence of cirrhotic patients that develop portal vein thrombosis in comparison to cirrhotic patients that do not develop portal vein thrombosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis

NCT02335580

Liver Cirrhosis Portal Vein Venous Thrombosis +2 more

COMPLETED

Portal Vein Thrombosis Relevance on Liver Cirrhosis: Italian Venous Thrombotic Events Registry

NCT01470547

Liver Cirrhosis Portal Vein Thrombosis

COMPLETED

Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis

NCT02069457

Liver Cirrhosis Portal Vein Thrombosis

COMPLETED

TIPS vs Endoscopic Therapy for Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis

NCT02485184

Portal Vein Thrombosis Liver Cirrhosis

UNKNOWN NA

Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis

NCT01326949

Decompensated Cirrhosis Portal Vein Thrombosis Bleeding Varices

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients newly diagnosed with portal vein thrombosis by imaging tests, that evaluate the extent and exclude tumoral origin, will be included (informed consent previously signed).

Anticoagulant treatment will be initiated according to clinical guidelines (if there is no contraindication) first with LMWH (low molecular weight heparin) and later with dicoumarin.

An abdominal CT will be performed to evaluate the extent and exclude tumoral origin; a gastroscopy to evaluate portal hypertension (and do prophylaxis if required) and thrombophilia study.

Patients will be followed by imaging and laboratory tests every 6 months; to evaluate the response to the treatment and detect any cirrhosis complication.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Vein Thrombosis Cirrhosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cirrhosis

Patients with cirrhosis will be followed looking about the event of portal vein thrombosis

Event of portal vein thrombosis

Intervention Type OTHER

There is no intervention over patients. They are followed during 3 years to look after any event of portal vein thrombosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Event of portal vein thrombosis

There is no intervention over patients. They are followed during 3 years to look after any event of portal vein thrombosis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cirrhosis diagnosed by liver biopsy or non-invasive methods/clinical, analytics or ultrasound usual criteria
* Portal vein thrombosis of newly diagnosed (defined as partial or complete obstruction of splenoportal vessels objectified by imaging with/without symptomatology) ≤ 6 months.
* Over 18 years old
* Want to participate (informed consent)

Exclusion Criteria

* Pregnant or lactating
* Patients with tumoral vein thrombosis or elevated alpha-fetoprotein or high suspicion of underlying neoplastic disease.
* Thrombocytopenia \< 25.000 .
* Patients with cavernomatosis or portal vein thrombosis already known.
* Patient refusal to participate
* Patients already treated with anticoagulants for other diseases (atrial fibrillation, pulmonary thrombosis...)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No